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The kidney is one of the most energy consuming tissues 
in the body, with approximately two-thirds of its oxidative 
substrate provided by fatty acids (1). Excess fatty acid in the 
cell is esterified to form triglyceride and stored in lipid 
droplets. While the entire kidney can utilize fatty acids, the 
cortex and the epithelial tubule cells depend on fatty acid 
oxidation (FAO) for ATP (2).
The cortex is also the site of large accumulations of neu-
tral lipids during kidney disease and injury (2). Pathways 
that contribute to lipid accumulation in the kidney are not 
well-established. Some studies suggest that during obesity, 
diabetes, and aging, an increase in the SREBPs leads to 
greater de novo fatty acid synthesis, which drives lipid accu-
mulation and decreases renal function (3–6). Other studies 
have shown that renal failure causes decreased FAO (7, 8), 
which could independently increase lipid accumulation.
Multiple pathways are dysregulated in chronic kidney 
disease (CKD), making this issue difficult to study. On the 
other hand, neutral lipid accumulation also occurs during 
fasting (9). In many tissues, such as the heart, muscle, and 
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adipose tissue, LPL and cluster of differentiation (CD)36 
are necessary for proper transport of fatty acids into the 
tissues (10, 11). LPL is synthesized by parenchymal cells 
and translocates to the endothelial surface, where it hydro-
lyzes VLDL and chylomicron triglycerides to produce 
NEFAs. NEFAs can then either diffuse through the mem-
brane in a process called “flip-flop” (12) or transfer across 
the membrane by a saturable receptor-mediated process 
(13). CD36 has been postulated to mediate active transport 
of NEFAs into cells (14). Like the heart, skeletal muscle, 
and adipose tissue, the kidney robustly expresses both LPL 
and CD36 (15, 16). However, in an unbiased assessment of 
renal genes in mice with diabetic kidney disease, Cd36 was 
reduced, as were other genes associated with renal FAO 
(17). This suggests that FAO and lipid uptake into the kid-
ney are coordinately regulated.
In the current study, we first determined NEFA uptake 
into the kidney during fasting and then modulated plasma 
NEFA levels and assessed whether this altered kidney triglyc-
eride accumulation. We then tested to determine whether 
triglyceride-rich lipoproteins or NEFAs were the source of 
kidney triglyceride stores. In addition, we tested to deter-
mine how kidney CD36 and LPL were affected by fasting and 
whether these known moderators of triglyceride metabolism 
affect fasting-induced lipid accumulation in the kidney.
MATERIALS AND METHODS
Animal studies
We used 10- to 16-week-old male and female C57BL/6 mice, 
Cd36/ mice (18), floxed Lpl mice (Lplfl/fl), inducible (i)Lpl/ 
mice, floxed Mttp (Mttpfl/fl) and liver-specific Mttp knockout mice 
(L-Mttp/) mice, and adipocyte-specific adipose triglyceride li-
pase (Atgl) knockout mice (AAKO) (19, 20). Mice were raised on 
a normal chow diet. Littermates were used as controls for all stud-
ies. All procedures were approved by the New York University 
Langone Medical Center, Washington University, State University 
of New York Downstate, and University of Pittsburgh Institutional 
Animal Care and Use Committees. Mice of each genotype were 
divided into two groups; one group was fasted 16 h overnight and 
the other was allowed to feed ad libitum for the same time pe-
riod. All mice were then euthanized with a lethal injection of 100 
mg/kg ketamine and 10 mg/kg xylazine. Animals were dissected 
open and then perfused by cardiac puncture in the heart with 5 
ml of PBS until the liver and kidneys blanched. Tissues were dis-
sected out, snap-frozen in liquid nitrogen, and stored at 80°C 
for further use. Kidneys were also bisected and embedded into 
Tissue-Tek OCT compound (Sakura) for oil-red O histology.
Poloxamer 407 (P407) was prepared in PBS as previously de-
scribed (21). Mice were injected intraperitoneally with 1 mg/g 
bodyweight of P407 and then fasted for 16 h. Control mice were 
injected with an equivalent volume of PBS.
iLpl/ animals were generated as described previously (22). 
Briefly, -actin-driven tamoxifen-inducible-Cre (Mer/Cre/Mer) 
transgenic mice were crossed with LPL-flanked loxP sites mice to 
obtain the -actin-MerCreMer/Lplfl/fl offspring, designated iLpl/. 
The iLpl/ mice were given an intraperitoneal injection of 1 mg of 
4-hydroxytamoxifen (Sigma) in peanut oil for five consecutive days.
3-adrenergic receptor agonist, CL 316,243 (Sigma), was dis-
solved in PBS and injected into C57BL/6 mice at 1 mg/kg at two 
time points (2:00 PM and 6:00 PM) (23). The mice were allowed 
to feed ad libitum and euthanized the following morning.
Microsomal triglyceride transfer protein (MTTP) was inhib-
ited using BMS-212122 [MTTP inhibitor (MTTPi)] as previously 
described (24). Briefly, the MTTPi was diluted in DMSO and 
given to mice orally at a dose of 1 mg/kg bodyweight for seven 
consecutive days. Control mice were given an equivalent volume 
of DMSO. After the final dose, mice were divided into two groups 
and either fasted overnight for 16 h or allowed access to food ad 
libitum and euthanized.
Measurement of plasma lipids and glucose
One hundred microliters of blood were drawn from each 
animal and then centrifuged at 10,600 g on a table top centrifuge 
for 10 min to obtain plasma. Plasma was used to measure triglyc-
erides and NEFA using the Thermo Scientific Infinity assay 
(Thermo Scientific) and the Wako NEFA kit, respectively. Glu-
cose was measured from whole blood using a One Touch Ultra 
2™ glucometer. Triglyceride-rich lipoproteins (density < 1.006 g/
ml) were separated by sequential density ultracentrifugation of 
plasma in a TLA100 rotor as described in Kako et al. (25).
Lipid extraction and measurement
The lipid extraction protocol was adapted from the Folch 
method (26) and modified slightly from Trent et al. (10). Briefly, 
approximately 100 mg of tissue were homogenized in 500 l of 
ice-cold PBS using stainless steel beads for 30 s in a bead beater 
homogenizer. From each sample, 50 l were removed for pro-
tein analysis, and 1.5 ml of 2:1 chloroform:methanol were added 
to the rest of the homogenate in a glass test tube. Samples were 
then centrifuged for 10 min at 2,050 g at 4°C. The lower organic 
phase was separated with a glass Pasteur pipette and blown dry 
with nitrogen gas. The dried lipid was then dissolved with 500 l 
of 2% Triton X-100 in chloroform, further dried, and then dis-
solved in double distilled water. The sample of tissue lysate put 
aside was used to assay protein content using Bradford reagent 
(Bio-Rad) following the manufacturer’s instructions. Using the 
tissue lipid extract, assays for triglyceride were performed using 
the previously described assay for plasma lipid. Lipid measure-
ments were normalized to protein content of each sample or mil-
ligram of tissue weight.
In vivo NEFA uptake
NEFA uptake was assessed in C57BL/6 mice either fasted 16 h 
overnight or allowed access to food ad libitum for the same time and 
in Cd36/ and Cd36fl/fl mice fasted 16 h overnight. The [1-14C]oleic 
acid (PerkinElmer Life Sciences) was complexed to 0.6% fatty acid-
free BSA (Sigma). Mice were injected intravenously with 1.5 × 106 
cpm of [1-14C]oleic acid-BSA and blood was collected at 0.5, 2, and 
5 min after injection, after which the mice were euthanized. Plasma 
was collected as previously described. The body cavity was perfused 
with 5 ml of PBS by cardiac puncture and tissues were extracted. 
Tissues were homogenized in 1 ml of PBS and radioactive counts 
were measured using a LS 6500 multipurpose scintillation counter 
(Beckman Coulter). For C57BL/6 mice, radioactivity per gram tis-
sue was normalized to average plasma NEFA levels in either the fed 
or fasted group. For Cd36/ and Cd36fl/fl mice, radioactivity per 
gram tissue was normalized to 2 min plasma cpm counts.
Renal gene expression
Total RNA was purified from an approximately 50 mg piece of 
kidney cortex using TRIzol reagent (Invitrogen) according to the 
instructions of the manufacturer. cDNA was synthesized using 
Verso cDNA kit (Thermo Scientific) and quantitative real-time 
PCR was performed with Power SYBR Green PCR Master Mix 
(Life Technologies) using a Quant Studio 7 Flex analyzer (Life 
Technologies). Genes of interest were normalized against 18s 
rRNA. Primer sequences are listed in supplemental Table S2.
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RNA sequencing
Raw sequencing data were received in FASTQ format and 
mapped against the hg19 human reference genome using Tophat 
2.0.9. The resulting BAM alignment files were processed using the 
HTSeq 0.6.1 python framework and respective hg19 General 
Transfer Format gene annotation, obtained from the UCSC data-
base. Differentially expressed genes (DEGs) were identified using 
Bioconductor package DESeq2 (3.2), which analyzes RNA se-
quencing data based on a negative binomial distribution model. 
To control for false discovery rate, resulting values were adjusted 
using the Benjamini and Hochberg method. Ingenuity Pathway 
Analysis was then performed on the DEG in order to determine 
the top canonical pathways being altered. Genes with an adjusted 
p-value <0.05 were determined to be differentially expressed. A 
heat map was created in Microsoft Excel, normalizing all samples 
to the fed group and expressing the values as fold change.
Lipidomics
Long-chain fatty acyl-CoAs, acyl carnitines, and ceramides were 
analyzed by targeted metabolomics as previously described (27–29). 
Briefly, approximately 20 mg of renal cortex were homogenized 
and extracted with cold 8:1:1 methanol:chloroform:water con-
taining known amounts of C17:0 acyl-CoA (Sigma-Aldrich,), iso-
tope-labeled carnitines (Cambridge Isotope Laboratories), and 
C17:0 and C25:0 ceramide (Avanti Polar Lipids) internal stan-
dards. An equal volume from each tissue sample was combined to 
generate a pool sample to monitor analytical variability. Cerami-
des were extracted following the method of Bligh and Dyer (30) 
and the organic layer was dried under vacuum and resuspended 
in 60:40 acetonitrile:isopropanol. As an additional control, a mix-
ture of seven standard ceramide compounds was simultaneously 
extracted and analyzed. Acyl-CoAs, acyl carnitines, and ceramides 
were quantified by LC/ESI-MS/MS in the multiple reaction mon-
itoring mode using an Agilent 6410 triple quadrupole MS system 
equipped with an Agilent 1200 LC system. Concentrations were 
calculated by ratios of peak areas of samples to known concen-
trations of internal standards. Data were normalized to tissue 
weight. All solvents were LC-MS grade (Sigma-Aldrich).
Histology
Frozen sections were cut to 10 M, air dried, fixed with 4% 
paraformaldehyde, and washed with double distilled water. Sec-
tions were rinsed with 60% isopropanol and stained with freshly 
prepared oil-red O for 15 min and rinsed again with 60% isopro-
panol. Sections were then placed in modified Mayer’s hematoxy-
lin for 1 min and washed with distilled water. Slides were then 
mounted with cover slips using glycerin jelly. Images were 
taken using a Leica SCN400F whole slide scanner.
Statistics
Data are expressed as mean ± SD. Data were analyzed by the 
use of unpaired Student’s t-test or two-way ANOVA Tukey’s mul-
tiple comparison tests.
RESULTS
FAO increases along with triglyceride accumulation in the 
kidney after a fast
To study lipid accumulation in the kidney, we used an 
overnight fast as a triglyceride accumulation model (9). 
After an overnight fast, plasma glucose in both male and 
female mice decreased by nearly half, while triglycerides 
and cholesterol were not significantly altered (Fig. 1A–C). 
NEFAs increased 2-fold (Fig. 1D). As in the heart and 
liver, an overnight fast induced triglyceride accumulation 
in the kidney; the average triglyceride increase was 3-
fold in males and 5-fold in females (Fig. 1E). This accumu-
lation occurred primarily in the renal cortex, as shown by 
oil-red O staining of kidney sections (Fig. 1F).
To assess which lipid pathways were changed in kidneys 
from fasted animals, mRNAs of proteins involved in FAO, 
de novo lipid synthesis, and lipid transport pathways were 
analyzed by RNA sequencing of whole kidney from fed 
and fasted mice. mRNA levels of genes that mediate de 
novo lipogenesis were decreased, including Fasn, squalene 
epoxidase (Sqle), acetyl-CoA carboxylase  (Acaca), and 
sterol regulatory element-binding transcription factor 1 
(Srebf1) and 2 (Fig. 2A). However, despite greater lipid 
accumulation, mRNA levels of genes involved in lipid oxi-
dation and mitochondrial pathways were increased, in-
cluding those of pyruvate dehydrogenase kinase 4 (Pdk4), 
alternative oxidase (Aox), carnitine palmitoyltransferase 1a 
(Cpt1a), and carnitine O-acetyltransferase (Crat) (Fig. 2A). 
PPAR (Ppara) and Ppard were increased and Pparg re-
mained unchanged (Fig. 2A). Among the more oxidative 
portions of the kidney, Ppara is the dominantly expressed 
isoform (31) Ingenuity pathway analysis using the KEGG 
database showed that PPAR signaling was the most differ-
entially regulated pathway, with 23 associated genes 
changed (Table 1). A majority of PPAR-regulated genes 
were also increased after fasting (Fig. 2B). In concordance 
with the RNA sequencing data, Aox, Cpt1a, and acetyl-CoA 
synthetase long-chain 1 (Acsl1) were all increased 4-fold 
when assessed by quantitative PCR (Fig. 2C). Genes associ-
ated with lipid uptake were also assessed. Cd36 mRNA lev-
els increased almost 2-fold after fasting by quantitative 
PCR, though it did not quite reach significance. Fatty acid 
transport protein 2/solute carrier family member 27 mem-
ber 2 (Fatp2/Slc27A2), a primarily intracellular enzyme 
that traps NEFAs by esterifying them to CoA (32), was un-
changed (Fig. 2C). In addition, the lipoprotein receptors, 
LDL receptor, LDL receptor related protein (Lrp)1, Lrp2 
(megalin), and VLDL receptor (Vldlr), remained un-
changed. While the Lpl mRNA level was unchanged, an-
giopoietin-like 4 (Angptl4), an LPL inhibitor, was increased 
9-fold. Lipid droplet-associated protein perilipin (Plin)2 
increased 20-fold and Plin5 increased 10-fold. Intracellular 
lipases needed to utilize triglyceride stored in lipid drop-
lets also increased; hormone sensitive lipase (Hsl/Lipe) 
mRNA increased 7-fold and adipose triglyceride lipase 
(Atgl/Pnpla2) 2-fold. Others have reported that, after a 
fast, both HSL and ATGL activation by phosphorylation 
increases in the kidney (33). Taken together, this gene ex-
pression profile suggests that, despite increased mRNA 
levels of genes regulating FAO and decreased mRNA levels 
of genes mediating de novo lipogenesis, the kidney stores 
excess fatty acids in lipid droplets during fasting. This sug-
gests an excess of fatty acid transport into the kidney.
Lipidomic changes
Lipidomics was performed to analyze fatty acid species in 
the kidney after an overnight fast. There was an overall 
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increase in long-chain acyl-CoAs (Fig. 3A), although signifi-
cance for changes in individual fatty acids could not be shown 
due to wide variation in the fasted group. Levels of the long-
chain acyl-carnitine, C16, decreased 10-fold (Fig. 3B). This 
is opposite to what was reported by Koves et al. (34) to hap-
pen in skeletal muscles. Additionally, a decline in long-
chain ceramides and their derivatives, glycosphingolipids, 
in the kidney was observed after fasting (Fig. 3C, D). An ex-
cess of ceramides is toxic to cells (35, 36). These data suggest 
that to compensate for increased lipid oxidation, uptake 
of either triglyceride-rich lipoproteins or NEFAs increases, 
leading to triglyceride, but not ceramide, accumulation.
Lipid accumulation in the kidney is dependent on serum 
NEFAs
To determine whether fasting increases uptake of 
albumin-bound NEFAs, we performed an uptake study of 
[14C]oleic acid in the fed and fasted state. After 5 min, nearly 
all the [14C]oleic acid tracer was cleared from the circulation 
(Fig. 4A). The liver took up a majority of fatty acids in both 
fed and fasted mice and accumulated more NEFAs during 
fasting. Similarly, kidney uptake of NEFAs was increased 
4-fold with fasting (Fig. 4B).
We next tested to determine whether altered plasma 
NEFA levels would lead to parallel changes in kidney 
triglycerides. To increase NEFAs in the fed state, we used a 
 adrenergic receptor agonist, CL 316,238. Plasma NEFAs 
were increased 2-fold over time with two intraperitoneal 
injections (Fig. 4C). This treatment increased kidney in-
tracellular triglyceride levels 15-fold (Fig. 4D); a similar 
triglyceride increase was found in liver, but not heart. To 
determine whether reduced circulating fatty acid levels 
would reduce kidney triglyceride after fasting, we studied 
mice with an adipocyte-specific deletion of Atgl (mice are 
denoted AAKO). As had been shown previously (20), AAKO 
mice have lower circulating NEFAs (Fig. 4E), and unlike 
floxed control mice (Atglfl/fl littermates), NEFAs decreased 
with fasting. Plasma triglycerides were also reduced in this 
model (Fig. 4F). Mirroring the liver, the kidney also had an 
40% reduction in fasting triglyceride content compared 
with fasted controls (Fig. 4G). Liver triglyceride accumula-
tion with fasting was reduced in AAKO mice, as was reported 
previously (20). These data demonstrate that renal triglyc-
eride during fasting is modulated by plasma NEFA levels.
Lipid accumulation in the kidney is not dependent on CD36
We then asked whether NEFA uptake required CD36, a 
known fatty acid transporter highly expressed in the kidney 
and increased 2-fold with fasting (Fig. 2C). However, up-
take of oleic acid into kidneys from Cd36/ mice was not 
decreased (Fig. 4H, I), and kidneys from Cd36/ mice had 
the same amount of triglyceride increase with fasting as 
did wild-type mice (Fig. 4J compared with Fig. 1E). Thus, 
the kidney does not require CD36 for fasting-induced lipid 
accumulation.
Triglyceride accumulation in the kidney does not require 
LPL or circulating lipoproteins
LPL is required for fasting triglyceride accumulation in 
the heart (10); like in the heart, but not in the liver, LPL is 
Fig. 1. Kidney triglycerides increased in both male and female mice after an overnight fast. A–E: Male and female mice were either fasted 
or given food ad libitum for 16 h. Blood was drawn to measure glucose and plasma lipids. Lipids were extracted for intracellular triglyceride 
measurements. A: Plasma glucose. B: Plasma triglycerides. C: Plasma total cholesterol. D: Plasma NEFAs. E: Kidney triglyceride content. F: 
Kidneys from male mice were formalin fixed and sectioned for oil-red O staining. Scale bar is representative of 100 M at 20× magnification. 
N = 4–6/group. *P < 0.05. Results are presented as mean ± SD. *Results compared by unpaired Student’s t-test within each sex group, no 
significant differences were found between male and female groups using the two-way ANOVA Tukey’s multiple comparison test.
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amply expressed in the kidney (15, 37). To assess whether 
LPL and lipoproteins are necessary for triglyceride accu-
mulation in the kidney, we injected mice with a surfactant 
compound, P407. P407 blocks the clearance of lipopro-
teins from the circulation and causes lipemia (38). In our 
mice, triglyceride increased from 50 mg/dl to over 5,000 
mg/dl (Fig. 5A). P407 also increased plasma NEFAs in 
both fed and fasted mice (Fig. 5B), likely due to associa-
tion with triglyceride-rich lipoproteins (10). P407 did not 
decrease triglyceride accumulation in the kidney after a 
fast, but led to a 20% increase in triglycerides during the 
fed state (Fig. 5C). Similar results were found in females 
(Fig. 5D–F) as in males.
To further explore the role of LPL, we studied mice with 
a tamoxifen-inducible deletion of LPL (iLpl/) (22) and 
assessed the changes in renal triglyceride accumulation be-
fore and after an overnight fast and compared them to 
floxed littermate (Lplfl/fl) controls also injected with tamox-
ifen. Two weeks after the final tamoxifen injections, plasma 
triglycerides increased more than 20-fold in both fed and 
fasted iLpl/ mice (Fig. 5G). Plasma NEFAs slightly in-
creased as well in iLpl/ mice after fasting (Fig. 5H). Tri-
glycerides in the kidney did not decrease, but rather 
increased by 25% after fasting, compared with the fasting 
iLplfl/fl group (Fig. 5I). This might be due to the increased 
fatty acids in iLpl/ mice after fasting.
We further explored whether lipoproteins are the source 
of fatty acids in the kidney by blocking MTTP, a key regulator 
of lipoprotein formation in the liver and small intestines 
(39). After a 16 h fast, BMS-212122, a MTTPi, decreased 
Fig. 2. The kidney in the fasted state upregulates lipid oxidation genes and downregulates lipid synthesis genes. RNA sequencing of fed 
and fasted male kidneys. Data presented as fold change normalized to the fed group. DEGs were identified with Bioconductor package DE-
seq2 (3.2) and Benjamini and Hochberg’s method was used to control for false discovery rate. A: Canonical genes in pathways related to lipid 
metabolism and mitochondrial membranes, lipid biosynthesis and lipid transport, and lipolysis. B: Canonical genes in the PPAR pathway. C: 
Quantitative PCR of selected lipid metabolism genes, normalized to ribosomal 18s. Experiments were performed in male mice, N = 3–5. 
*P < 0.05. Results are presented as mean ± SD. Results for quantitative PCR were compared by unpaired Student’s t-test.
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plasma and VLDL triglycerides by approximately 40% 
(Fig. 6A). MTTPi treatment increased liver triglycerides 
(Fig. 6B), but unexpectedly, the kidney triglyceride level 
trended toward an increase (Fig. 6B). It has been previ-
ously shown that the kidney can synthesize and secrete 
lipoproteins (9).
To test whether some of the effects of plasma triglyceride 
reduction were masked by intra-renal MTTP inhibition, 
we fasted mice with a liver-specific knockdown of Mttp 
(L-Mttp/) (40) for 16 h. Plasma triglycerides were de-
creased several fold (Fig. 6C), while liver triglycerides in 
the L-Mttp/ mice were increased. Fasting kidney tri-
glyceride levels were slightly affected by loss of Mttp in 
the liver (Fig. 6D). These results suggest that circulating 
lipoproteins and LPL play a minimal role, if any, in lipid 
accumulation in the kidney during a fast.
DISCUSSION
Lipid accumulates in the kidney cortex during diseased 
and nondiseased states. The mechanism(s) by which these 
lipids accumulate is unclear. In addition, little information 
is available to determine whether lipid accumulations are 
pathological or physiological. In this study, we evaluated 
the physiologic regulation of kidney lipids during fasting 
and explored the roles of lipid uptake processes that are 
known to affect triglyceride storage in other tissues. Unlike 
muscles, kidney lipid storage is not dependent on either 
LPL or CD36 and correlates with plasma NEFAs. Further 
data indicated that kidney triglyceride accumulation was 
dependent on NEFAs from the plasma. Using [14C]oleic 
acid, we showed that the kidney indeed takes up more 
NEFAs during a fast (Fig. 4B). We further showed that in-
creasing serum NEFA levels in the fed state with CL 315,343, 
a 3-adrenergic receptor agonist, markedly increased kidney 
triglyceride accumulation (Fig. 4C, D). At the same time, 
heart triglycerides were reduced with CL 315,343 treatment; 
these data are consistent with our previous studies indicat-
ing that circulating triglycerides and not NEFAs are the 
source of heart triglyceride (10). Conversely, lowering cir-
culating NEFAs using AAKO mice (Fig. 5F) led to reduced 
kidney triglyceride (Fig. 5G). Our results confirm studies 
TABLE 1. Ten most significantly altered pathways in the kidney between the fed and fasted state
KEGG Pathway P Genes
PPAR signaling pathway 8.36E-08 SLC27A1, ACOX1, CPT1B, SCD2, CPT2, ACADM, EHHADH, FADS2, PCK2, 
ACADL, DBI, CPT1A, PCK1, CYP4A10, ACSL1, CYP27A1, HMGCS2, 
CYP4A31, APOC3, FABP4, ACSL4, ACAA1B, SLC27A2, ANGPTL4
Fatty acid metabolism 4.71E-06 ACOX1, CPT1B, ACAA2, ACADM, CPT2, EHHADH, ACADL, HADHA, CPT1A, 
HADHB, ACADVL, CYP4A10, ACSL1, CYP4A31, ACSL4, ACAA1B
Phosphatidylinositol signaling system 0.030783 PLCB4, PIK3C2G, PLCG1, INPP5K, PIK3CB, PI4KA, DGKZ, DGKH, DGKI, 
INPP5D, PLCB1, ITPR1
Biosynthesis of unsaturated fatty acids 1.99E-05 PECR, ACOX1, SCD2, FADS1, ACOT2, FADS2, ACOT1, ACAA1B, ACOT4, 
HADHA, ACOT3
Adipocytokine signaling pathway 0.034582 CPT1B, ACSL1, LEPR, IKBKG, ACSL4, PCK2, STAT3, AKT3, CPT1A, AKT2, 
PCK1
Arginine and proline metabolism 0.020652 SAT1, ODC1, GATM, GLUD1, ARG2, MAOB, CKMT1, DAO, NOS3, CKB
Glycine, serine, and threonine metabolism 0.002628 GLYCTK, GATM, MAOB, PHGDH, GCAT, DAO, PSAT1, CBS, GLDC
Amino sugar and nucleotide sugar metabolism 0.019358 GALK1, RENBP, GNPDA1, MPI, GM8615, CMAH, UGDH, NAGK, UXS1, PMM1
Valine, leucine and isoleucine degradation 0.024859 ACAA2, DBT, ACADM, BCAT2, HMGCS2, EHHADH, ACAA1B, HADHA, 
HADHB
Terpenoid backbone biosynthesis 3.68E-05 DHDDS, MVD, HMGCS2, HMGCR, FDPS, MVK, IDI1, PDSS1
Ingenuity pathway analysis was performed on the DEGs to determine most canonical pathways being altered, according to the KEGG pathway 
database. Pathways are listed in order of most significantly different.
Fig. 3. Ceramides and glycosphingolipids are low-
ered in the fasted kidney. Lipidomics were performed 
using LC/ESI-MS/MS on kidneys of mice that were 
fasted or given food ad libitum for 16 h. A: Long-chain 
acyl CoAs. B: C16 acyl-carnitine. C: Ceramides. D: Gly-
cosphingolipids. Experiments were performed in 
male mice, N = 4–5/group. *P < 0.05. Results are pre-
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Fig. 4. Plasma free fatty acids determine kidney triglyceride content and do not require CD36 for transport. A, B: [1-14C]oleic acid (OA) 
was injected intravenously into male mice. The presence of radioactive signal was measured in plasma or tissue homogenate using a LS 6500 
multipurpose scintillation counter. A: Plasma clearance of [1-14C]OA over time. B: Liver and kidney 14C label 300s after injection. Experi-
ments were performed in male mice, N = 4–5/group. C, D: Male mice were injected with CL 316,243 at 2 and 6 h time points, and blood 
samples were drawn at indicated points in order to measure NEFA concentration in the blood. Mice were euthanized at the 16 h time point 
to collect tissues, N = 4–5/group. C: Plasma NEFAs over time after two CL 316,243 injections (indicated by arrows). D: Tissue triglyceride 
content 16 h after first injection. E–G: Female adipocyte Atgl knockout mice (AAKO) or littermate controls were fasted for 16 h and eitha-
nized, N = 6–8/group. Plasma NEFA (E) and triglyceride (F) of AAKO and control mice in the fed and 16 h fasted state. G: Kidney and liver 
triglyceride of AAKO and control mice after a 16 h fast. H–J: [1-14C]OA was injected intravenously into male mice. Presence of radioactive 
signal was measured in plasma or tissue homogenate as mentioned before. H: Plasma clearance of [1-14C]OA over time, N = 8–9/group. I: 
OA uptake in fasted Cd36fl/fl and Cd36/ N = 8–9/group. Kidney lipids were extracted from kidneys of Cd36/ in the fed and fasted state 
using 2:1 methanol:chloroform. J: Kidney triglyceride in fed and fasted Cd36/, N = 3/group.*P < 0.05, #P < 0.05. *Comparison between 
feeding status using unpaired Student’s t-test. #Comparison between genotype using the two-way ANOVA Tukey’s multiple comparison test. 
Results are presented as mean ± SD.
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that measured arterial versus venous blood and showed 
that the kidney takes up more fatty acid during fasting (41).
Fasting-induced lipid accumulation was associated with 
increased expression of genes that modulated fatty acid 
metabolism and triglyceride storage and not with greater 
accumulation of ceramides. In many tissues, dysfunction is 
associated with the accumulation of potentially toxic lipids, 
such as ceramides. The nonpathological storage of NEFAs 
as triglyceride was suggested by an increase in the lipid 
droplet proteins, Plin2 and Plin5 (Fig. 2A), indicating a ca-
pacity for safely storing excess triglyceride. Following fast-
ing, our lipidomic analysis showed a trend to an increase 
in fatty acyl CoAs, a decrease in C16 acyl-carnitine, and 
a decrease in long-chain ceramides and glycosphingolip-
ids. An increase in skeletal muscle acyl-carnitines was as-
sociated with incomplete FAO in high-fat diet-fed 
animals (42). Therefore, the decrease in renal acyl-carni-
tines in the fasted state could result from more complete 
-oxidation. An increase in ceramides is associated with 
cellular apoptosis, as well as insulin resistance (35, 36, 43). 
There is a dearth of information on the role of ceramides 
in kidney injury and some of what is reported is conflicting. 
Sas et al. (28) reported that in a diabetic obesity model of 
kidney injury, long-chain ceramides and glycosphingolip-
ids are reduced. Others have reported an increase in glyco-
sphingolipids, a product of ceramides, associated with 
diabetic nephropathy and mesangial expansion (44).
To achieve a global perspective on the changes in kidney 
lipid metabolism during fasting, we performed RNA se-
quencing of the kidney. Several enzymes associated with 
increased ceramide production were reduced. mRNA levels 
of sphingomyelin phosphodiesterase 1 (Smpd1) which is re-
sponsible for hydrolyzing sphingolipids to form cerami-
des in the fasted kidney, were reduced 2-fold and serine 
palmitoyltransferase subunits 1 and 2 (Sptlc1 and Sptlc2) that 
control de novo synthesis of ceramide were unchanged 
(supplemental Table S1).
FAO appeared to increase with fasting, and de novo 
synthesis did not appear to increase. Though this was not 
measured directly, our indirect data strongly suggest that 
Fig. 5. LPL is not required for triglyceride accumulation in the kidney. A–C: Male mice were injected with P407 or PBS equivalent and 
fasted or given food ad libitum for 16 h (top panel). Plasma triglycerides (A) and plasma NEFAs (B). C: Kidney triglyceride content. N = 4–5/
group. D–F: P407 repeated in females (middle panel) with same conditions as males. G–I: Tamoxifen inducible LPL floxed (iLplfl/fl) and 
knockout (iLpl/) male mice were fasted or given ad libitum access to food for 16 h. Blood was drawn for measurement of plasma lipids and 
kidney lipids were extracted and measured (bottom panel). Plasma triglycerides (G) and NEFAs (H). I: Triglyceride content of kidneys. 
N = 4–6/group. *P < 0.05, #P < 0.05. *Comparison between feeding status using unpaired Student’s t-test. #Comparison between genotype 
or treatment using the two-way ANOVA Tukey’s multiple comparison test.
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this is the case. mRNA levels of genes in the lipid synthesis 
pathway were downregulated, while genes in the lipid oxi-
dation pathway, mitochondrial electron transport, and fatty 
acid transport were upregulated (Fig. 2A). The PPAR path-
way was the most differentially regulated pathway among 
those in the KEGG database, which have been shown to 
regulate FAO genes (Table 1) (45). These data suggest 
that, along with greater triglyceride storage, the kidney ac-
cumulates an excess supply of substrate for storage while 
catabolizing more lipids for energy. During fasting, many 
tissues burn fats rather than glucose and, like the kidney, 
some of these tissues also store lipids, perhaps as a local 
energy supply to use in times of greater energy requirements 
(46). The gene expression profile in the kidney implies 
greater FAO during fasting. This differs from the heart, 
which also accumulates triglyceride during fasting, but does 
not show this same pattern of increased FAO genes (10).
The increase in FAO during fasting is contrary to what 
is reported in kidney injury. FAO-associated genes are 
downregulated in the kidneys of mice with folic acid-in-
duced nephropathy, as well as in humans with CKD (7). 
However, during early diabetic kidney disease, when esti-
mated glomerular filtration rate is not significantly de-
creased, -oxidation is increased (28, 29). Therefore, 
fasting and early diabetes may reflect a need for greater 
energy requirements by intact tubular cells in the kidney, 
while CKD illustrates an example of pathologic injury 
and lipid accumulation due to reduced lipid oxidation.
We sought to determine the transporter required for 
renal NEFA uptake. A logical transporter was CD36; our 
quantitative PCR showed an increased trend of Cd36 
mRNA levels in the kidney during the fasted state (Fig. 2C). 
CD36 is a long-chain fatty acid transporter that is important 
for the uptake of fatty acids in various tissues (47). Surpris-
ingly, [14C]oleic acid uptake in fasted Cd36/ mouse kid-
neys was the same as in controls (Fig. 4I). Triglyceride 
content in the kidney also tripled after a fast in Cd36/ 
mice (Fig. 4J). Overall triglyceride levels in the fasted 
Cd36/ mouse kidneys were higher when compared with 
fasted wild-type mice (Fig. 1E). This is likely due to elevated 
NEFA in the plasma due to the defect in peripheral NEFA 
uptake by the heart and skeletal muscle (48). Our data 
demonstrate that CD36 is not necessary for fatty acid 
uptake in kidneys from fasted mice and, at first glance, 
appear to contradict the studies of Kang et al. (7), who 
showed that overexpression of Cd36 in the proximal tubule 
increases triglyceride accumulation in the kidney. While 
forced overexpression of Cd36 will lead to accumulation 
of triglyceride in the kidney, we show that it is not necessary 
for fatty acid transport or triglyceride accumulation in the 
kidney. It is possible that other fatty acid transporters, such 
as those from the FATP family (49, 50), are responsible for 
uptake in the kidney. However, these FATPs are predomi-
nantly intracellular and, rather than being transmembrane 
transporters, are thought to trap intracellular fatty acids 
by acyl-CoA synthetase actions (32). Another possible 
Fig. 6. Triglyceride-rich lipoproteins are not a signifi-
cant source of triglyceride in the kidney. A, B: Whole 
body blockade of MTTP was achieved using BMS-
212122 (MTTPi, N = 4–5/group) given orally for 7 days 
or vehicle (DMSO) equivalent to mice. Data obtained 
after a 16 h fast. A: VLDL triglyceride levels obtained 
from ultracentrifugation of plasma of mice treated with 
MTTPi or vehicle. B: Kidney and liver triglyceride con-
tent of fasted mice treated with either MTTPi vehicle. 
C, D: Liver-specific blockade of MTTP was achieved 
with a liver-specific knockout of MTTP (L-Mttp/, 
N = 4–6/group). C: Plasma triglycerides of L-Mttp/ 
mice versus floxed littermate controls. D: Kidney and 
liver triglyceride content of L-Mttp/ mice versus lit-
termate controls. E: Summary figure of research data: 
1) During fasting Angptl4 inhibits LPL, so that triglyc-
erides on lipoproteins cannot be hydrolyzed, thus fatty 
acid-loaded albumin is the primary exogenous source 
of fatty acids for the kidney. 2) Though CD36 is amply 
expressed on the kidney, it is not required for the trans-
port of fatty acids into the kidney during fasting, which 
might involve nonreceptor diffusion across the mem-
ber. 3) Though CD36 does not appear to act as a major 
transporter, it does not discount that other transport-
ers may exist. 4) Once inside the cell, fatty acid is shut-
tled to the mitochondria where it can be oxidized for 
ATP. If the rate of fatty acid flux into the cells is far 
greater than the cells capacity for oxidization, excess 
fatty acids are stored in lipid droplets. Stored fatty acids 
can also be released from the lipid droplets and oxi-
dized. Experiments were performed in male mice. 
*P < 0.05, #P < 0.05. *Comparison between feeding sta-
tus using unpaired Student’s t-test. #Comparison be-
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route of NEFA uptake into the kidney is via uptake of al-
bumin. However, the very rapid turnover of NEFAs com-
pared with that of albumin makes this hypothesis unlikely. 
Moreover, mRNA levels of purported albumin transport-
ers, such as Lrp2, were decreased according to our RNA 
sequencing (Fig. 2A). Alternatively, fatty acids may enter 
the kidney via passive diffusion through the membranes, 
which can occur when fatty acid levels are high (51).
We tested to determine whether fasting-induced renal 
triglycerides were derived from circulating lipoproteins and 
whether kidney triglyceride accumulation requires LPL hy-
drolysis of triglyceride to release NEFAs. Blocking or deleting 
LPL did not decrease triglyceride accumulation in the kidney 
after a fast. Although LPL is abundant in the kidney, during 
the fasted state, increased expression of Angptl4 may inhibit 
LPL actions (Fig. 2A). Angptl4 is thought to dissociate the 
LPL dimer, thus inhibiting its enzymatic action (52). Our 
data are consistent with those of Ruge et al. (53) who re-
ported that kidney LPL activity is highest in the fed state 
and lowest in the fasted state of mice; we now show that this 
is likely due to Angptl4. Because LPL loss did not play a role 
in lipid accumulation in the kidney in either the fed or fasted 
state, the role of LPL in the kidney is unclear.
In support of our finding that LPL does not play a major 
role in lipid accumulation, we found that circulating tri-
glyceride levels did not correlate with the intracellular lipid 
content of the kidney. We lowered circulating triglycerides 
two ways: pharmacologically with an MTTPi (Fig. 6A) and 
genetically by specifically knocking out Mttp in the liver 
(Fig. 6C). The kidney, like the liver, is able to form and re-
lease lipoproteins (9). This is highlighted by our data show-
ing that the kidney retains triglycerides when treated with 
MTTPi, with a trend to increased kidney triglyceride con-
tent after a fast (Fig. 6B). When we lowered circulating li-
poprotein levels by deleting Mttp in the liver, plasma 
triglyceride levels were markedly reduced, but triglyceride 
content in the kidney remained mostly unchanged, although 
some of the fasted L-Mttp/ mice had reduced triglycer-
ides (Fig. 6D). Because some NEFAs associate with lipopro-
teins, this reduction in kidney triglyceride may be due 
to fewer circulating lipoproteins carrying NEFAs. These 
MTTP inhibition studies showed that the kidney does not 
largely rely on exogenous lipoproteins for triglycerides.
In conclusion, we have found that the kidney primarily 
takes up NEFAs rather than lipoproteins, and high serum 
levels of NEFAs cause greater lipid accumulation in the 
kidney. Figure 6E summarizes the findings from our study. 
The kidney, despite having high levels of expression of 
Cd36 and Lpl, does not require either of these proteins for 
fatty acid uptake during fasting. During fasting, LPL ac-
tions in the kidney are likely inhibited by increased Ang-
ptl4. Taken together, our data show that the kidney behaves 
similarly to the liver with respect to certain aspects of lipid 
metabolism (e.g., lipid uptake does not involve LPL or 
CD36). Both the liver and the kidney receive abundant 
cardiac output of blood, are intensely metabolically active, 
and might not depend on a high affinity localized fatty 
acid uptake pathway. Rather, a lower affinity, but higher 
capacity, fatty acid uptake process may be sufficient to 
extract fatty acids from the circulation. This high volume of 
blood supply to the kidney may also be why NEFAs on albu-
min are sufficient for lipid accumulation in the kidney. 
Comparably, less perfused tissues, such as skeletal muscle 
and adipose tissue, would require the large amounts of 
fatty acids, in the form of triglyceride, and also the actions 
of a high affinity NEFA transporter, such as CD36. It should 
be noted that the molecular events required for NEFA up-
take by the liver are incompletely characterized and might 
require a number of known or unique transporters (54). 
The fatty acids are either shuttled to the mitochondria for 
oxidation or to lipid droplets for storage in the form of 
triglyceride. These stored triglycerides can also be hydro-
lyzed by HSL and ATGL to release fatty acids for oxidation. 
Little in the way of kidney lipid metabolism has been stud-
ied despite lipid accumulation being present in nearly all 
forms of kidney injury. Our data add to our understanding 
of lipid metabolism in the nondiseased kidney.
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